PURE Bioscience (OTCMKTS:PURE) reports quarterly results

PURE Bioscience (OTCMKTS:PURE – Get Free Report) released its quarterly financial results on Friday. According to the report, the company reported ($0.01) earnings per share for the quarter. PURE Bioscience had a negative net margin of 194.80% and a negative return on equity of 717.03%. During the quarter, the company’s revenue was $0.44 million.

PURE Bioscience Price Performance

Shares of OTCMKTS:PURE opened at $0.07 on Friday. PURE Bioscience has a 1-year low of $0.06 and a 1-year high of $0.17. The company’s 50-day moving average price is $0.08 and its 200-day moving average price is $0.10.

About PURE Bioscience

(Get the free report)

PURE Bioscience, Inc develops and markets antimicrobial products that provide solutions to health and environmental issues related to pathogen control and hygiene in the United States and around the world. The company produces and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial that provides residue protection and is also formulated with other compounds.

Featured Stories

Get news and ratings for PURE Bioscience every day – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for PURE Bioscience and related companies with MarketBeat.com’s FREE daily email newsletter.